References
- Menichetti F, Del Favero A. The role of gram-positive therapy in the neutropenic patient. J Antimicrob Chemother 1991; 27 (Suppl B): 51-60.
- Steiner M, Villablanca J, Kersey J et al. Alpha-strepto-coccal shock in bone marrow transplantation patients. Blood 1988; 72 (Suppl 1): 409A.
- Hughes WT, Bodey GP, Feld R et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unex-plained fever. J Infect Dis 1990; 161: 381–396.
- Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis 1991; 164: 907–916.
- Huijgens PC, Ossenkoppele GJ, Weijers TF et al. Imipenem-cilastatin for empirical therapy in neutropenic patients with fever: an open study in patients with hematolog-ical malignancies. Eur J Haematol 1991; 46: 42–46.
- Freifeld AG, Walsh T, Marshall D et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995; 13: 165–176.
- Joshi JH, Newman KA, Brown BW et al. Double beta-lactam regimen compared to an aminoglycoside/beta-lactam regimen as empiric antibiotic therapy for febrile granulocy-topenic cancer patients. Supp Care Cancer 1993; 1: 186–194.
- Studena M, Hlavacova E, Hel'pianska L et al. Teicoplanin plus pefloxacine versus teicoplanin plus netilmicin in empiric therapy of febrile patients with cancer and neutropenia. Chemotherapy 1994; 40 (6): 431–434.
- Rodzinski E, Kern WV, Reichle A et al. Once-daily ver-sus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993; 31 (4): 585–598.
- Johnson PR, Liu-Yin JA, Tooth-JA. A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients. J Antimicrob Chemother 1992; 30 (2): 203–214.
- Thomas JF, Hernandez LM, Penarrubia MJ et al. Early bacterial infections in 103 patients treated with bone marrow transplantation. Sangre-Barc 1994; 39 (3): 191-196.
- Leong WA, Jewesson PJ. A retrospective evaluation of imipenem use in bone marrow transplant patients. Chin Ther 1994; 16 (5): 753–766.
- EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikadn for empirical therapy of gram-nega-tive bacteriemia in cancer patients with granulocytopenia. N Engl J Med 1987; 317: 1692-1698.
- Lipman B, Neu HC. Imipenem, a new carbapenem antibiotic. Med Clin N Am 1988; 7: 567–579.
- Bosi A, Fanci R, Guidi S et al. Environmental control measures in a new Bone Marrow Transplant Unit. Haematologica (Suppl 73): 1988; 3: 238.
- Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cydosporine compared with cyclosporine alone for prophy-laxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.
- Wilson WH, Jain V, Bryant G et al. Phase I and II study of high-dose ifosfamide, carboplatin and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol 1992; 10 (11): 1712–1722.
- Kojima A, Shinkai T, Soejima Y et al. A randomized prospective study of imipenem-cilastatin with or without amikacin as an empirical antibiotic treatment for febrile neu-tropenic patients. Am J Clin Oncol 1994; 17 (5): 400–404.